<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04504916</url>
  </required_header>
  <id_info>
    <org_study_id>2140-002</org_study_id>
    <secondary_id>VLS-101-0003</secondary_id>
    <secondary_id>MK-2140-002</secondary_id>
    <nct_id>NCT04504916</nct_id>
  </id_info>
  <brief_title>A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)</brief_title>
  <official_title>A Phase 2 Study of VLS-101 in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VelosBio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VelosBio Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study evaluating the efficacy, safety, pharmacokinetics, immunogenicity, and&#xD;
      pharmacodynamics of zilovertamab vedotin in participants with metastatic solid tumors&#xD;
      including triple-negative breast cancer (TNBC), non-squamous non-small-cell lung cancer&#xD;
      (NSCLC), estrogen receptor-positive breast cancer, progesterone receptor-positive breast&#xD;
      cancer and human epidermal growth factor 2 positive carcinoma of breast.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">January 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 18, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to ~18 months</time_frame>
    <description>The percentage of participants who achieve a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in tumor dimensions</measure>
    <time_frame>Baseline, Up to ~30 months</time_frame>
    <description>Percent change in tumor dimensions, defined as the percent change from baseline in the sum of the longest diameters of non-nodal target lesions and the shortest diameters of nodal target lesions will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>TTR, defined as the time from the start of study treatment to the first documentation of objective tumor regression will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>DOR, defined as the interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>PFS, defined as the interval from the start of study treatment to the earlier of the first documentation of disease progression or death from any cause will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>TTF, defined as the time from the start of study treatment to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>OS, defined as the interval from the start of study treatment to death from any cause will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experienced an adverse event (AE)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experienced an AE will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who discontinued study treatment due to an AE</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinued study treatment due to an AE will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of zilovertamab vedotin</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of total antibody</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of monomethyl auristatin E (MMAE)</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of zilovertamab vedotin</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Tmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of total antibody</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Tmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of MMAE</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Tmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of zilovertamab vedotin</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>AUC of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of total antibody</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>AUC of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of MMAE</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>AUC of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) of zilovertamab vedotin</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Vd of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd of total antibody</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Vd of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd of MMAE</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>Vd of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of zilovertamab vedotin</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>CL of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of total antibody</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>CL of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of MMAE</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>CL of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t½) of zilovertamab vedotin</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>t½ of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ of total antibody</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>t½ of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ of MMAE</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>t½ of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz) of zilovertamab vedotin</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>λz of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of total antibody</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>λz of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of MMAE</measure>
    <time_frame>Pre-dose and 0.5, 2 and 4 hours post-dose on Day 1 of Cycle 1; pre-dose and 0.5 hours post-dose on Day 1 of each subsequent cycle (up to ~30 months); Non-dose day samples on Day 8 and Day 15 of Cycle 1; each cycle = 21 days</time_frame>
    <description>λz of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of circulating zilovertamab vedotin-reactive anti-drug antibodies (ADA)</measure>
    <time_frame>Pre-dose on Day 1 of each 21-day cycle (up to ~30 months)</time_frame>
    <description>Titer of circulating zilovertamab vedotin-reactive ADA determined by blood samples collected pre-dose will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Triple-negative Breast Cancer (TNBC)</condition>
  <condition>Non-squamous Non-small-cell Lung Cancer (NSCLC)</condition>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>Progesterone Receptor-positive Breast Cancer</condition>
  <condition>Human Epidermal Growth Factor 2 Positive Carcinoma of Breast</condition>
  <arm_group>
    <arm_group_label>Zilovertamab vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive zilovertamab vedotin at 2.5 mg/kg given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue until progressive disease or discontinuation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zilovertamab vedotin</intervention_name>
    <description>Intravenous infusion of 2.5 mg/kg</description>
    <arm_group_label>Zilovertamab vedotin</arm_group_label>
    <other_name>MK-2140</other_name>
    <other_name>VLS-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a confirmed diagnosis of solid tumor.&#xD;
&#xD;
          -  Has metastatic disease that has progressed during or following previous treatment&#xD;
             appropriate for the disease type.&#xD;
&#xD;
          -  Presence of radiographically measurable disease.&#xD;
&#xD;
          -  Is willing to provide tumor tissue.&#xD;
&#xD;
          -  Has adequate organ function.&#xD;
&#xD;
          -  Has a negative test or adequate therapy for human immunodeficiency virus (HIV),&#xD;
             hepatitis B, and/or hepatitis C.&#xD;
&#xD;
          -  Has completed all prior therapy.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum pregnancy test.&#xD;
&#xD;
          -  Both male and female subjects must be willing to use adequate contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has peripheral neuropathy of Grade &gt;1.&#xD;
&#xD;
          -  Has a malignancy involving the central nervous system.&#xD;
&#xD;
          -  Has another major cancer.&#xD;
&#xD;
          -  Has an uncontrolled ongoing infection.&#xD;
&#xD;
          -  Has significant cardiovascular disease.&#xD;
&#xD;
          -  Has a known diagnosis of liver cirrhosis.&#xD;
&#xD;
          -  Is pregnant or breastfeeding.&#xD;
&#xD;
          -  Has had major surgery within 4 weeks before the start of study therapy.&#xD;
&#xD;
          -  Has known tumor resistance or intolerance to a prior MMAE-containing drug.&#xD;
&#xD;
          -  Is concurrently participating in another therapeutic or imaging clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Orlando ( Site 0003)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-303-2090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>551-996-4725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson ( Site 0001)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-794-1226</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pd</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

